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Abstract. A decrease in serum Mg+2 is associated with airway hyper-reactivity and impaired pulmonary 
function.  The purpose of this study was to determine if decreased serum Mg+2 levels in patients with 
chronic obstructive pulmonary disease (COPD) are associated with acute exacerbations.  In a retrospective 
study, the charted serum Mg+2 levels in 100 COPD patients were examined.  These included 50 patients 
who presented with an acute exacerbation of COPD and 50 stable patients.  Chart review was sequential 
within both groups.  Serum Mg2+ levels in the stable COPD patients averaged 0.91 ± 0.10 mmol/L (mean 
± SD) with a 95% CI of 0.88 – 0.94 mmol/L.  Patients undergoing an exacerbation had significantly lower 
serum Mg+2 levels (0.77 ± 0.10 mmol/L; CI, 0.74 – 0.79; p <0.0001).  Logistic regression of the dichotomous 
outcomes as a function of serum Mg+2 concentration demonstrated a highly significant association (c2 = 
41.26; p <10-5).  These data were subjected to receiver-operator characteristic (ROC) analysis for decision 
levels (DL) and the area under the ROC curve was determined to be 0.85 ± 0.04 (CI, 0.78 – 0.93).  The 
optimum DL was determined to lie between 0.80 mmol/L (OR = 14.33; sensitivity 70%; specificity 86%) 
and 0.84 mmol/L (OR = 11.16; sensitivity 84%; specificity 68%).  These data suggest that at the lower 
range of the reference interval, serum Mg+2 levels are associated with an increased risk of exacerbation of 
symptoms in COPD patients.  Furthermore, they suggest a DL that is useful for predicting clinical 
outcomes in these patients and serving as a target value for therapy.
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Introduction
A growing body of evidence suggests that Mg+2 
deficiency contributes to exacerbations of asthma 
and, as a corollary, that Mg+2 is useful in alleviating 
bronchospasm in these patients [1-3].  Although 
the precise mechanism of this action is unknown, 
it has been suggested that Mg+2 plays a role in the 
maintenance of airway patency via relaxation of 
bronchial smooth muscle [4].
 Chronic obstructive pulmonary disease 
(COPD) represents an overlap of chronic bronchitis 
and emphysema, and patients with COPD have an 
element of asthmatic bronchitis [5]. Bronchospasm 
is a contributing factor in their inability to clear 
secretions. This may result in reduced pulmonary 
gas exchange with consequences such as decreased 
quality of life and repeated hospitalization [6].
 Thus, Mg+2 may have a role in maintaining 
disease stability in COPD patients. That not 
withstanding, the relationship between serum 
Mg+2 levels and outcome with regard to disease 
flares in COPD patients has not been, hitherto, 
thoroughly explored.  The study described herein 
uses an observational model, the case-control study, 
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to explore possible associations between COPD 
stability and exacerbation and serum Mg+2 levels.
Materials and Methods
Protocol. The retrospective study was designed on a case-
control model, for which subjects in both groups had 
previously been diagnosed with COPD based on dynamic 
pulmonary function test results (ratio of 1-sec forced 
expiratory volume, FEV1/ forced vital capacity, FVC <70) 
according to the European Respiratory Society Task Force 
recommendations [7]. Other than that criterion and the 
requirement that there was a serum Mg+2 measurement made 
upon admission or at the time of the ambulatory visit, the 
subjects were unselected and were entered in reverse sequence 
until the target number of 50 per group was enrolled. 
Assignment to a group was made on the basis of criteria 
described under patient characteristics, below.  
 All subjects were seen at St. Joseph’s Regional Medical 
Center, a 750-bed, tertiary care teaching hospital in New 
Jersey.  Because the study involved no risk to the subjects, all 
of whom were coded with non-identifiable numbers, the St. 
Joseph’s Institutional Review Board placed this study in the 
exempt category.
 
Patient characteristics. The case group included subjects who 
presented with an exacerbation of COPD requiring 
hospitalization based on the criteria of Anthonisen et al [8], 
ie, presence of either shortness of breath or severe coughing 
with or without increased sputum volume.  The control group 
was drawn from COPD patients who presented for routine 
office visits.  Because the study protocol involved sequential 
enrollment of patients in each group, no attempt was made to 
match the subjects by age or sex.  
Analytical method. Serum Mg+2 was analyzed by the 
calmagite spectrophotometric technique [9], as part of a 
routine clinical chemistry test panel.  The reference interval in 
our laboratory is 0.70 to 1.03 mmol/L.
Statistical methods. For this study, a was set at 0.05.  Post-
hoc power analysis, based on the differences between the 2 
groups at n = 50 per group, indicated that the study achieved 
a power > 0.99;  p values were all two-sided.
 Descriptive statistics were computed with confidence 
intervals set at 95%; data were tested for normality with the 
D’Agostino-Pearson omnibus normality test [10].  Because 
the data for serum Mg+2 levels were not normally distributed, 
a non-parametric inter-group comparison test, assuming 
independent assortment (the Mann-Whitney test), was used. 
Age data, which were normally distributed and had approx-
imately equal variances, were compared by unpaired t-test. 
Fisher’s exact test was used to analyze contingency tables for 
categorical variables. 
 The correlation between outcomes (stable, exacerbation) 
and the predictor variable was based on logistic regression 
analysis for which correlation was tested by chi-square 
distribution (c2).  Decision levels (cut-offs) for prediction of 
outcomes were determined by receiver-operator characteristic 
(ROC) analysis.   
 With the exception of logistic regression, for which a 
web-based routine was used [11], calculations were performed 
with Prism software (GraphPad Corp., San Diego, CA) using 
a personal computer. 
Results
Patient characteristics. There was no significant 
difference in the age of the subjects in the 2 study 
groups.  Patients with exacerbation averaged 70.4 ± 
10.5 (SD) yr while stable patients averaged 67.1 ± 
11.0 yr (p = 0.134). Gender distributions were 
equivalent, with male/female ratios of 27/23 for the 
patients presenting with exacerbation and 30/20 
for the subjects in the stable group (p = 0.687).
Comparison of serum Mg+2 levels in study groups. 
The serum Mg+2 levels associated with both groups 
of patients were distributed as shown in Fig. 1. 
Stable COPD patients averaged 0.91 ± 0.10 mmol/
L (mean ± SD) with a 95% CI (CI95) of 0.88 – 0.94 
mmol/L.  Patients undergoing an exacerbation had 
significantly lower serum Mg+2 concentrations 
(0.77 ± 0.10 mmol/L; CI95, 0.74 to 0.79 mmol/L; 
Mann-Whitney U = 375.5; p < 0.0001).   
 Logistic regression analysis indicated strong 
correlation between Mg+2 concentration and 
outcome (c2 = 41.26; p <10-5).  Fig. 2 shows the 
logistic regression probability curve, demonstrating 
that the probability of exacerbation approaches 0 at 
the higher end of serum Mg+2 concentrations.
Decision levels. The data were subjected to receiver-
operator characteristic (ROC) analysis and the 
resultant ROC curve is presented in Fig. 3.  The 
plot (area under the curve, 0.85 ± 0.04; CI, 0.78 – 
0.93) suggests that serum Mg+2 discriminates quite 
well between the 2 groups of patients.  
 To assess the presumed risk of exacerbation 
that lower serum Mg+2 may impose on COPD 
patients, we evaluated the odds ratios at 3 increments 
between the confidence intervals of the group 
means, ie, between 0.80 and 0.88.  These data are 
listed in Table 1.  All cross-tabulations used Fisher’s 
exact test to test for significance of the contingency 
tables.  For each of the intervals given in Table 1, p 
is < 0.0001.
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Fig. 1.  Distribution of serum Mg+2 concentrations in stable COPD patients and in patients experiencing exacerbations. 
Confidence intervals (CI) at 95% are indicated. 
Fig. 2.  Logistic regression probability curve. The curve 
demonstrates how the probability of exacerbation decreases 
with increasing serum Mg+2  concentration.
Fig. 3.  Receiver-operator characteristic curve of the data in 
Fig. 1.  Three decision levels between the upper 95% CI of 
exacerbation (0.79) and the lower CI of stability (0.88) are 
indicated.
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Discussion
Recent statistics on the impact of COPD [6] 
suggest a direct cost of $18 billion to care for the 
nearly 6% of the American public who have this 
disease.  Because much of the impact of COPD is 
due to the constellation of symptoms that is 
commonly termed an exacerbation, major emphasis 
in the management of patients with COPD must 
be the maintenance of stability.  Bach et al [12] 
note that antibiotics, bronchodilators, cortico-
steroids, and non-invasive positive-pressure ventil-
ation remain the mainstays of therapy, but they 
point out the need for the identification of risk 
factors and the limited utility of diagnostic 
predictors of the course of COPD.
 There is growing awareness of a role for magnes-
ium in pulmonary disease. Fiaccadori et al [13] 
examined serum and muscle magnesium levels in a 
group of 32 patients admitted to a pulmonary 
intensive care unit with a diagnosis of COPD and 
acute respiratory failure and compared these with 
an age- and sex-matched control group consisting 
of 30 healthy subjects.  Mean serum Mg+2 was 
slightly lower in the patients (0.85 ± 0.14 mmol/L) 
than in the controls (0.90 ± 0.10 mmol/L), but this 
difference was not statistically significant.  However, 
they noted a significant difference in both muscle 
Mg+2 and K+.  Lum [14] recognized the problem of 
hypomagnesemia in acute and chronic care hospital 
populations.  In a retrospective study of data from 
2 Boston-area hospitals, he observed a substant-
ially higher incidence of hypomagnesemia in the 
acute care population compared to the chronic-
care group, which was predominantly psychiatric.  
 Much of the impetus for the recognition of 
Mg+2 as both a risk factor and potential therapeutic 
agent in patients with COPD comes from the 
relatively well-established role of Mg+2 in the 
treatment of acute asthma.  In the period 1999–
2001, 4 randomized, controlled clinical trials [15-
18] examined the efficacy of iv magnesium sulfate 
in the management of acute asthma attacks and 
yielded conflicting results.  In a meta-analysis of 9 
other studies, Alter et al [1] noted an improvement 
of 16% in spirometric tests of pulmonary function 
and suggested that magnesium sulfate therapy be 
considered for treatment of bronchospasm in the 
absence of contraindications for its use.  The utility 
of nebulized magnesium sulfate for inhalation 
therapy is less clear. Although some benefit was 
reported by Nannini et al [19], more recent studies 
[2,20] of magnesium sulfate as an adjunct to 
albuterol in an emergency department demonstrated 
no improvement in pulmonary function.  However, 
since no change of serum Mg+2 levels was observed, 
it is unclear that the total amount of delivered 
magnesium achieved a therapeutic level.  
 The role of dietary magnesium is also unclear. 
In a study of 2,633 adults, FEV1 was increased 
significantly when dietary magnesium was increased 
by 100 mg/day [21]. Epidemiologic data from cross-
sectional studies suggest some efficacy of dietary 
magnesium supplementation [22], although a well-
executed experimental study did not support the 
contention that dietary magnesium supplementation 
is effective [23].
 In this report, we examined serum Mg+2 levels 
in an unselected group of COPD patients with 
clear symptoms of exacerbation and compared 
Table 1.  Cross-tabulation for exacerbation of COPD associated with varying levels of serum Mg+2.  DL is decision level (cut-off) 
for serum Mg+2 concentration (mmol/L).  Sensitivity,  specificity, and odds ratio (OR, odds of stability/odds of exacerbation if 
serum Mg+2 > DL) are given at each level with their corresponding 95% confidence intervals (CI) in parentheses.  For all  levels, 
p = <0.0001 by Fisher’s exact test.
Decision Level (DL)            Sensitivity   Specificity        Odds Ratio           
 0.80      0.70 (0.55 to 0.82) 0.86 (0.73 to 0.94) 14.33 (5.26 to 39.05)
 0.84      0.84 (0.71 to 0.92)   0.68 (0.53 to 0.80) 11.16 (4.26 to 29.19)
 0.88      0.92 (0.81 to 0.98)   0.56 (0.41 to 0.70) 11.50 (3.53 to 37.45)
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these to a group of patients reporting for routine 
clinic visits and in no apparent distress from the 
sequelae of bronchospasm generally considered to 
indicate an exacerbation.  Our stable subjects had 
significantly higher concentrations of serum Mg+2 
and analysis of our data suggests that serum Mg+2 
may serve as a risk factor.  Our data suggest that a 
threshold level of serum Mg+2 of approximately 
0.85 mmol/L may be a useful therapeutic target for 
magnesium supplementation, as well as a level 
below which clinicians may give increased vigilance 
for signs of exacerbation in their COPD patients.
 The data that we report were derived from an 
epidemiologic model (ie, a case-control study) and 
we recognize the limitations inherent in that design. 
Nevertheless, we consider the observed association 
between serum Mg+2 and exacerbation of COPD 
to be substantial both in terms of the statistical 
power of the study and the clarity of our findings.
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